TargetMol

Sitafloxacin

Product Code:
 
TAR-T6349L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6349L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sitafloxacin, a new generation of broad-spectrum oral fluoroquinolones, is highly effective against many Gram-positive, Gram-negative, and anaerobic clinical isolates (including strains resistant to other fluoroquinolones).
CAS:
127254-12-0
Formula:
C19H18ClF2N3O3
Molecular Weight:
409.82
Purity:
0.98
SMILES:
N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F

References

Kong Y, Geng Z, Jiang G, et al.Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China.Heliyon.2023 Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation. Helicobacter. 2016 Aug;21(4):286-94. doi: 10.1111/hel.12286. Epub 2015 Nov 27. PubMed PMID: 26612407. Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter. 2016 May 23. doi: 10.1111/hel.12319. [Epub ahead of print] PubMed PMID: 27213463. Nakajima T, Okui T, Ito H, Nakajima M, Honda T, Shimada Y, Tabeta K, Akazawa K, Yamazaki K. Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1779-87. doi: 10.1128/AAC.02575-15. PubMed PMID: 26729495; PubMed Central PMCID: PMC4775917. Manosuthi W, Wiboonchutikul S. Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus. 2016 Apr 5;5:410. doi: 10.1186/s40064-016-2044-5. eCollection 2016. PubMed PMID: 27069830; PubMed Central PMCID: PMC4821846.